Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema

Simple item page
dc.contributor.authorSrinivasan, Sen_US
dc.contributor.authorHande, Pen_US
dc.contributor.authorShetty, Jen_US
dc.contributor.authorMurali, Sen_US
dc.date.accessioned2020-04-10T01:57:59Z
dc.date.available2020-04-10T01:57:59Z
dc.date.issued2018-01
dc.description.abstractPurpose: The purpose of this study is to study the benefit of addition of oral fenofibrate to the current regimen of diabetic macular edema (DME) management and quantify its effect on macular thickness and visual function in DME. Methods: Fifty-three eyes of 50 patients were randomized into treatment (Group A) (oral fenofibrate 160 mg/day) and control groups (Group B). Both groups underwent treatment of DME as per the standard treatment protocol of our hospital including intravitreal injections (anti-vascular endothelial growth factor/steroid) and grid laser. Patients were followed up every 2 months to note the visual acuity and central macular thickness (CMT) for 6 months. Results: Our groups were matched with respect to age (P = 0.802), mean diabetic age (P = 0.878), serum HbA1C levels (P = 0.523), and serum triglyceride levels (P = 0.793). The mean reduction in CMT was 136 ? in Group A and 83 ? in Group B at the end of 6 months. This difference was statistically significant (P = 0.031). Visual acuity improvement was 0.15 in Group A and 0.11 in Group B at the end of 6 months (P = 0.186). On subgroup analysis in Group A, we found that there was no difference in reduction of CMT between hypertensives and normotensives (P = 0.916), in patients with normal triglyceride levels and increased triglyceride levels (P = 0.975). Conclusion: Addition of fenofibrate to the standard protocol of DME management seems to facilitate reduction of CMT and probably have an added benefit on the visual functions.en_US
dc.identifier.affiliationsDepartment of Vitreo Retina, Bangalore West Lions Super Speciality Eye Hospital, Bengaluru, Karnataka, Indiaen_US
dc.identifier.citationSrinivasan S, Hande P, Shetty J, Murali S. Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Indian Journal of Ophthalmology. 2018 Jan; 66(1): 98-105en_US
dc.identifier.issn0301-4738
dc.identifier.issn1998-3689
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/196545
dc.languageenen_US
dc.publisherAll India Ophthalmological Societyen_US
dc.relation.issuenumber1en_US
dc.relation.volume66en_US
dc.source.urihttps://dx.doi.org/10.4103/ijo.IJO_566_17en_US
dc.subjectDiabetic macular edemaen_US
dc.subjectfacilitating reduction of edemaen_US
dc.subjectfenofibrateen_US
dc.titleEfficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edemaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijo2018v66n1p98.pdf
Size:
1.46 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Ophthalmology